Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. - Test2 - elhamkhani - TriplyDB

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

http://www.wikidata.org/entity/Q33743791

about

Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus Type I interferon blockade in systemic lupus erythematosus: where do we stand?Biomarkers for childhood-onset systemic lupus erythematosus Current perspectives on systems immunology approaches to rheumatic diseases.Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis Gene expression profiles in a rabbit model of systemic lupus erythematosus autoantibody production Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Real-time, aptamer-based tracking of circulating therapeutic agents in living animals.Daily Moderate Exercise Is Beneficial and Social Stress Is Detrimental to Disease Pathology in Murine Lupus Nephritis Advances in systems biology approaches for autoimmune diseases Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside.Assessing the human immune system through blood transcriptomics.Interferon-alpha: a therapeutic target in systemic lupus erythematosus IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE).Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays Type I interferon in the pathogenesis of lupus.Mathematical framework for human SLE Nephritis: disease dynamics and urine biomarkers.A unifying hypothesis for scleroderma: identifying a target cell for scleroderma.Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells Combining DNA-microarray data in systemic lupus erythematosus.Interferon alpha in systemic lupus erythematosus Recent advances in the genetics of systemic lupus erythematosus.Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.Using gene expression to improve the power of genome-wide association analysis.Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus.CXCR3 in T cell function.The role of CXCR3 in the induction of primary biliary cirrhosis.Cell-specific type I IFN signatures in autoimmunity and viral infection: what makes the difference?IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation.Type I interferon and systemic lupus erythematosus.Cytokine disturbances in systemic lupus erythematosus.

P2860

Q26782454-A778C918-6DBF-4E74-A42C-41396F5D3050 Q26822662-00FE2521-B420-44EC-B10B-A5F240163B74 Q26865441-BC6C9DED-15A5-4CF8-B97A-B145446C17D0 Q27007470-3EC6A704-0AC3-42C6-B248-14ABEA2DA09F Q27687400-925EF305-43B6-45BB-8E08-78B08DF21710 Q28265144-EFF7BD15-08DE-4D95-86E6-AD57311B3095 Q28301151-5CF141C7-702A-4A63-BBF5-592F471D7C70 Q28535303-9577625B-33F9-43EA-B7F0-8A4F9114F5A1 Q30496834-55A3287D-723D-4134-A47E-A91566BF304A Q30645037-10D519CD-58EC-4A82-88BD-5C0BF5E866ED Q33570021-0044E198-7854-4A4A-A8A1-A6BFEC510626 Q33603442-97C719BF-264C-4F8A-B25B-56D423B67032 Q33619013-31027A01-C02C-4209-92C6-0089600CF4E5 Q33622723-F3659AD7-6501-42B4-911F-55BAFEC333D8 Q33629522-2BCB56F5-83D7-41EE-9573-0E1E5EB71DFC Q33744320-09C90E25-E0AA-44C9-B3FD-D78A9C3A10D5 Q33801351-AD32D3DC-FC80-47C4-8BA2-C84324B02B78 Q33826259-E975F06F-5F88-4626-B8A3-46C595F14E17 Q33829507-7DF29FAF-204D-4C8B-9673-BBC83DB77996 Q33852174-1F2D6548-5E47-43F3-9739-2FB79A5B6277 Q33881710-3BD70E5B-C6D9-4B95-992B-500BECEA6D0A Q33889221-39B4E5F4-0FF6-4E19-871C-452B22467929 Q33915692-5B3FC7C0-8219-4469-B3D7-4BA8C1E722AA Q33922380-C13C72A3-C7F8-436F-9642-B72D380303E6 Q33961179-263B3B93-9775-4D01-8448-DA617540BAF4 Q33964547-9FCA8684-0ECE-453C-91F7-F1C9C8594D64 Q34027495-C91B291F-CD68-411D-B9DF-84FE10E389FA Q34027578-4EF4C20B-FD8A-4147-8429-3670731668FB Q34125423-3C4732BA-EF81-4555-B229-56470FC2DC83 Q34149941-919BBB58-A783-47DC-B8BE-B5DBC80A65A8 Q34161393-760C238A-C726-4044-8274-58C375A5AE0D Q34240254-B9415CDA-4A0B-4CEB-BF48-596B960C442D Q34583337-19BE0B5C-BC9F-4BE1-BE42-C8D1DCA29B80 Q34726782-A0883E4C-287E-4B37-BCC2-49DF8E6B257C Q35008551-63A1BAC0-E3EC-4B5D-AE10-7814A8E0F518 Q35082621-8D2EA4EE-B01D-43E8-BAF8-B2C0501EB140 Q35118781-F312C327-4ADB-4A6C-AA2C-3E3677643D0C Q35334977-97662584-5F67-4248-AB6A-6FBDEF21D9D9 Q35549980-25F767EA-6EB0-46D3-B5FE-841BDDEA9DFD Q35617573-C3A4B6D7-F108-497C-B0F3-CF6A82017E38

P2860

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.

http://www.wikidata.org/entity/Q33743791

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Interferon-regulated chemokine ...... activity: a validation study.

@ast

Interferon-regulated chemokine ...... activity: a validation study.

@en

type

label

Interferon-regulated chemokine ...... activity: a validation study.

@ast

Interferon-regulated chemokine ...... activity: a validation study.

@en

prefLabel

Interferon-regulated chemokine ...... activity: a validation study.

@ast

Interferon-regulated chemokine ...... activity: a validation study.

@en

P1433

Q33743791-91A87492-2413-48F7-88C7-5625E903CB53

P1476

Q33743791-26B182E9-EAB0-4D4A-B2A8-E03B057E9512

P2093

Q33743791-07649CDD-7C22-4EFF-BD2D-1A518CFA2D15

Q33743791-2D85BB91-AD55-454D-82A8-254B49F603C4

Q33743791-2D9D80F5-0F68-4EA4-B674-2FC7CDC26BD1

Q33743791-42FCC3A4-2E17-4895-BC52-ACE5D9DBD02F

Q33743791-524736C9-B4F9-4C51-92D4-D7D3E66AC137

Q33743791-D55D1066-1B95-4EDC-994D-9D2D6E665A64

Q33743791-DA861034-A278-4396-B09D-94E62AAF535E

P2860

Q33743791-0D466182-701D-42F1-BFCC-F4BE745BC470

Q33743791-11F07405-ACAD-4763-9521-7F517A2C6AC1

Q33743791-12DCBABC-D2D9-4B79-811F-537BF3FCD06C

Q33743791-18EFC290-81F5-41DD-A669-692F167580DD

Q33743791-42F51CBA-0601-4C1F-8532-C34E893BB327

Q33743791-4B6B6F0A-3D1D-44A2-B343-BE4DE6B3E2B4

Q33743791-4DECD133-EE73-4B32-BD9F-2292667C533F

Q33743791-6A770D38-A2D9-4507-886C-4441EEA8266F

Q33743791-717F8941-FD82-42DA-BE0D-0AE2B155C489

Q33743791-89C715D6-759A-42D1-8ABA-D93291C97BD2

P304

Q33743791-8983D5AC-9D9B-4E41-B19A-B4121C9B6B21

P31

Q33743791-48D34FDB-8EC0-462C-8540-AF40E3498692

P356

Q33743791-E42452B2-F4D6-42EF-950C-F7DAF40E101E

P433

Q33743791-C77B47AF-91E0-4FAD-B6AB-7F2C6431E229

P478

Q33743791-CBA4CA88-D3F9-43AA-9B14-59507D6A88B1

P50

Q33743791-0F0ADB92-EBF2-4FB1-8357-E2A8C354A13C

Q33743791-59208322-4CB5-4308-8844-92BBBF61D034

Q33743791-A71384BA-63C8-4CBB-A9CE-3E580CC16194

P577

Q33743791-662E435C-B225-41FA-8F6B-89947E3CFA4B

P5875

Q33743791-8576C05A-1DB1-4BE3-BAB8-F6F4CD6C782B

P698

Q33743791-4CC749D5-DEC8-431E-9CEA-4D006F556A6B

P921

Q33743791-1AE015AD-97AC-4355-8CB2-B5135A2B9DE7

P932

Q33743791-233BCBCA-C7D8-4A42-9CCF-318E4F6539CB

P356

P1433

Arthritis & Rheumatology

P1476

Interferon-regulated chemokine ...... activity: a validation study.

@en

P2093

Catherine Slattery

http://www.w3.org/2001/XMLSchema#string

Emily C Baechler

http://www.w3.org/2001/XMLSchema#string

Franak M Batliwalla

http://www.w3.org/2001/XMLSchema#string

Jason W Bauer

http://www.w3.org/2001/XMLSchema#string

Joseph Wilson

http://www.w3.org/2001/XMLSchema#string

Thearith Koeuth

http://www.w3.org/2001/XMLSchema#string

Timothy W Behrens

http://www.w3.org/2001/XMLSchema#string

P2860

Cluster analysis and display of genome-wide expression patterns

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.

A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.

Type I interferon correlates with serological and clinical manifestations of SLE

Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus.

Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.

P304

3098-3107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.24803

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Angela Panoskaltsis-Mortari

Michelle A. Petri

Peter K. Gregersen

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26856842

http://www.w3.org/2001/XMLSchema#string

P698

19790071

http://www.w3.org/2001/XMLSchema#string

P921

P932

2842939

http://www.w3.org/2001/XMLSchema#string